The heartburn drug ranitidine is off the market with potential to return in the US and internationally, but study results suggesting a link to elevated diagnosis rates for some types of cancer could mark the beginning of the end of the ingredient’s future.
A study published online by the Journal of the American Medical Association on 29 January included in vitro tests with...




